Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial

SIMPLE SUMMARY: The lung immune prognostic index (LIPI) is proposed as a simple risk scoring tool to differentiate differences in survival from immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC). The tool has not been evaluated for performance in a NSCLC cohort initia...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers (Basel)
Hauptverfasser: Hopkins, Ashley M., Kichenadasse, Ganessan, Abuhelwa, Ahmad Y., McKinnon, Ross A., Rowland, Andrew, Sorich, Michael J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI 2021
Schlagworte:
Communication
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7967121/
https://ncbi.nlm.nih.gov/pubmed/33803256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13051176
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge